More about Bayer CropScience Limited
Fundamentals for Bayer CropScience Limited
Regulatory Filings for Bayer CropScience Limited
From Cost Center to Strategic Core: The Top 10 Trends Transforming Finance in 2026
CFOs Seize the Tech Purse Strings: How 2026 Budgets Are Fueling the AI Transformation
From Agentic AI to Tokenized Assets: The Fintech Trends Reshaping Financial Services
Forex Focus: How a Weakening Indian Rupee Could Reshape Markets in Q1 2026
Fundamentals for Bayer CropScience Limited
Business Operations:
Sector: Basic MaterialsIndustry: Agricultural Inputs
Bayer CropScience Limited engages in the manufacture, sale, and distribution of insecticides, fungicides, herbicides, and various other agrochemical products and corn seeds in India, Germany, Bangladesh, and internationally. It provides medicines primarily in the therapeutic areas of cardiology, gynecology, diabetes, oncology, and ophthalmology; and computed tomography, X-Ray, and magnetic resonance imaging devices. In addition, the company offers consumer health products that are used as a daily health solution to treat minor illnesses, as well as sells and distributes hybrid seeds, such as corn and paddy. Further, it provides digital farming products comprising FarmRise and other digital applications, such as drones for spray services, etc., as well as provides various technologies, such as remote sensing, IoT sensors, GPS, artificial intelligence, and data analytics to monitor and manage crop growth, soil quality, weather patterns, and other factors. The company also exports its products. Bayer CropScience Limited was founded in 1863 and is based in Thane, India.
Revenue projections:
BAYERCROP is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.
Financial Ratios:
| currentRatio | 0.000000 |
|---|---|
| forwardPE | 28.443815 |
| debtToEquity | 3.266000 |
| earningsGrowth | 1.798000 |
| revenueGrowth | 0.047000 |
| grossMargins | 0.395060 |
| operatingMargins | 0.092480 |
| trailingEps | 149.280000 |
| forwardEps | 168.753740 |
BAYERCROP's Forward PE ratio suggests the stock price is reasonable in relation to earnings. It's not overpriced, providing room for future growth, making the stock a potentially valuable investment for those seeking long-term gains.
With a forward EPS greater than its trailing EPS, BAYERCROP is forecasted to be more profitable this year than last. This growth expectation reflects confidence in the company's earnings potential and suggests an improving financial trajectory for the year ahead.
Price projections:
The gradual downward revision of BAYERCROP's price projections signals decreasing confidence in the company's future performance. Analysts are adjusting their expectations, reflecting uncertainty about BAYERCROP's growth potential.
Recommendation changes over time:
The analysts' recent buy bias for Bayer CropScience Limited indicates strong confidence in the stock's future performance. This could encourage more investors to view Bayer CropScience Limited as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
Understanding Divergent House Price Movements Worldwide
The 2026 Tariff Tipping Point: When Trade Policy Reaches the Consumer
From Caracas to Commodities: The Market Impact of U.S.–China Friction